|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Similarly, the three MALT lymphoma associated chromosome translocations, namely t(1;14)(p22;q32)/BCL10-IGH, t(14;18)(q32;q21)/IGH-MALT1,and t(11;18)(q21;q21)/BIRC3 (API2)-MALT1, are also capable of activating both canonical and non-canonical NF-κB pathways.
|
27452667 |
2016 |
|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We examined five cases of API2-MALT1 fusion-positive MALT lymphoma of the lung.
|
27600807 |
2016 |
|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Conversion of the LIMA1 tumour suppressor into an oncogenic LMO-like protein by API2-MALT1 in MALT lymphoma.
|
25569716 |
2015 |
|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The API2-MALT1 fusion oncoprotein is created by the recurrent t(11;18)(q21;q21) chromosomal translocation in mucosa-associated lymphoid tissue (MALT) lymphoma.
|
23770847 |
2014 |
|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In this study, we examined 14 cases of thymic MALT lymphomas for API2-MALT1 fusion using multiplex reverse transcription polymerase chain reaction and looked for trisomy 3, trisomy 18 and abnormalities of MALT1 and IGH genes using fluorescence in situ hybridization.
|
22243778 |
2012 |
|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
BIRC3 inactivation in SMZL recurred because of somatic mutations that disrupted the same RING domain that in extranodal marginal zone lymphoma is removed by the t(11;18) translocation, which points to BIRC3 disruption as a common mechanism across marginal zone B-cell lymphomagenesis.
|
21881048 |
2011 |
|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Pulmonary mucosa-associated lymphoid tissue lymphoma is unique in that chronic inflammation is rare and that API2-MALT1 fusion, resulting from t(11;18)(q21;q21), occurs frequently.
|
21396678 |
2011 |
|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We demonstrate that the API2-MALT1 fusion oncoprotein created by the recurrent t(11;18)(q21;q21) in mucosa-associated lymphoid tissue (MALT) lymphoma induces proteolytic cleavage of NF-κB-inducing kinase (NIK) at arginine 325.
|
21273489 |
2011 |
|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Thus, the c-IAP2/MALT1 fusion protein activates NF-κB by two distinct mechanisms, and loss of c-IAP2 E3 activity in vivo is sufficient to induce abnormalities common to MALT lymphoma.
|
21048983 |
2010 |
|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Mucosa-associated lymphoid tissue (MALT) lymphoma is characterized by t(11;18)(q21;q21)/API2-MALT1, t(1;14)(p22;q32)/BCL10-IGH and t(14;18)(q32;q21)/IGH-MALT1, which commonly activate the nuclear factor (NF)-kappaB pathway.
|
20520640 |
2010 |
|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to clarify predictive factors for response to eradication therapy in cases of Helicobacter pylori (H. pylori)-positive API2-MALT1-negative gastric mucosa-associated lymphoid tissue (MALT) lymphoma.
|
19385974 |
2009 |
|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
As we observed MALT1-API2 to be an efficient target of its own E3 ubiquitin ligase activity, our data suggest that this inherent instability of MALT1-API2 prevents its accumulation and renders a potential effect on MALT lymphoma development via destabilization of BCL10 unlikely.
|
19279678 |
2009 |
|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Successful radiotherapy in a patient with primary rectal mucosa-associated lymphoid tissue lymphoma without the API2-MALT1 fusion gene: a case report and review of the literature.
|
17570523 |
2008 |
|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Significantly, 98% of all cIAP2-MALT1 fusion proteins retain the UBA domain, suggesting that ubiquitin-binding contributes to the oncogenic potential of cIAP2-MALT1 in MALT lymphoma.
|
18931663 |
2008 |
|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
AlteredExpression
|
disease |
LHGDN |
Long-term follow-up of gastrectomized patients with mucosa-associated lymphoid tissue lymphoma: need for a revisit of surgical treatment.
|
18216531 |
2008 |
|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The well-known translocations identified in MALT lymphomas include t(11;18)/API2-MALT1, t(1;14)/IGH-BCL10, and t(14;18)/IGH-MALT1.
|
18927281 |
2008 |
|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We assessed the incidence and clinical significance of the MALT lymphoma-associated genetic abnormalities t(11;18)/API2-MALT1, t(1;14)/BCL10-IGH, t(14;18)/IGH-MALT1, t(3;14)/FOXP1-IGH, and extra copies of MALT1 and FOXP1 in gastric MALT lymphomas from Japan.
|
17525089 |
2007 |
|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The translocations t(6;18;11)(q24;q21;q21) and t(11;14;18)(q21;q32;q21) lead to a fusion of the API2 and MALT1 genes and occur in MALT lymphomas.
|
17339192 |
2007 |
|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The recurrent translocation t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue (MALT) lymphoma results in the expression of an API2.MALT1 fusion protein that constitutively activates NF-kappaB.
|
17287209 |
2007 |
|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
API2-MALT1 fusion transcript does not appear to be associated with either histological variant of primary intraoral MALT lymphoma.
|
18158571 |
2007 |
|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
These results reveal cIAP2 as an inhibitor of antigenic signaling and implicate its dysfunction in MALT lymphomas.
|
16395405 |
2006 |
|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
AlteredExpression
|
disease |
LHGDN |
These results reveal a physiological function of cIAP2, identify Bcl10 upregulation as a unifying molecular mechanism for MALT lymphomas, and define the mechanism and effects of this upregulation in t(11;18)-positive MALT lymphomas.
|
16775419 |
2006 |
|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
Biomarker
|
disease |
LHGDN |
These results reveal cIAP2 as an inhibitor of antigenic signaling and implicate its dysfunction in MALT lymphomas.
|
16395405 |
2006 |
|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The t(11;18)(q21;q21) API2/MALT1 translocation is a specific chromosomal abnormality in extranodal marginal B-cell lymphomas of the mucosa-associated lymphoid tissue (MALT) type, particularly in those occurring in the stomach and lungs.
|
17153776 |
2006 |
|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We recently demonstrated that API2-MALT1 can induce transactivation of the API2 gene through NF-kappaB activation, thus highlighting a positive feedback-loop mechanism of self-activation by upregulating its own expression in t(11;18) MALT lymphomas.
|
16572204 |
2006 |